Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,430
datasets available to search
ShareScore release 0.9.0
Dataset results
3,430 results for “PD”
Functionalized ionic liquid coatings in the Pd-catalyzed selective hydrogenation of acetylene in ethylene-rich feeds
<p>Raw data and python script as well as instructions for data evaluation</p>
Canberra PIPS detector PD 5000-75-500 AM (aka Mario I): performance data
<p>Model: PD 5000-75-500 AM</p> <p>Serial number: 101948</p> <p>Lot number: 3560.317A.24.1</p> <p>CERN internal name: Mario I</p>
DATASET - Results permeation tests double-skin Pd-based membranes, conventional Pd-based membranes and porous membranes
<p>Dataset used for:</p> <p><span>W. J. R. Ververs, M. Ongis, A. Arratibel, L. Di Felice, and F. Gallucci, “On the modeling of external mass transfer phenomena in Pd-based membrane separations,” <em>Int. J. Hydrogen Energy</em>, vol. 71, no. April, pp. 1121–1133, 2024, doi: 10.1016/j.ijhydene.2024.04.337.</span></p> <p>Contains permeation data of the following membranes:</p> <table> <tbody> <tr> <td> <p><strong>Porous membranes</strong></p> </td> <td> <p><strong> </strong></p> </td> </tr> <tr> <td> <p> S</p> </td> <td> <p>Porous Al<sub>2</sub>O<sub>3</sub> support</p> </td> </tr> <tr> <td> <p> S-YSZ/Al<sub>2</sub>O<sub>3</sub></p> </td> <td> <p>Porous YSZ/Al<sub>2</sub>O<sub>3</sub> on support</p> </td> </tr> <tr> <td> <p> S-HT</p> </td> <td> <p>Porous hydrotalcite on support</p> </td> </tr> <tr> <td> <p><strong>Conventional Pd-based membranes</strong></p> </td> <td> <p> </p> </td> </tr> <tr> <td> <p> S-PdAg</p> </td> <td> <p>Supported PdAg membrane</p> </td> </tr> <tr> <td> <p> S-Pd</p> </td> <td> <p>Supported Pd membrane</p> </td> </tr> <tr> <td> <p><strong>Double-skin Pd-based membranes</strong></p> </td> <td> <p> </p> </td> </tr> <tr> <td> <p> S-PdAg-YSZ/Al<sub>2</sub>O<sub>3</sub></p> </td> <td> <p>DS-PdAg membrane with YSZ/Al<sub>2</sub>O<sub>3</sub> protective layer</p> </td> </tr> <tr> <td> <p> S-PdAg-HT</p> </td> <td> <p>DS-PdAg membrane with hydrotalcite protective layer</p> </td> </tr> </tbody> </table>
Supplementary material 1 from: Scheffrahn RH, Bourguignon T, Akama PD, Sillam-Dussès D, Šobotník J (2018) Roisinitermes ebogoensis gen. & sp. n., an outstanding drywood termite with snapping soldiers from Cameroon (Isoptera, Kalotermitidae). ZooKeys 787: 91-105. https://doi.org/10.3897/zookeys.787.28195
Table S1 : Explanation note: Sources and GenBank accession numbers of mitochondrial sequences used for Fig. 1.
lil, left ilium;; lti, left tibia; pd, pedal digits; and ub, unidentified bony element. The white box indicates the position from which the sample was taken for histological analysis. Scale bars, 10 mm (a, c, d), 20 mm (b). in A new Jurassic scansoriopterygid and the loss of membranous wings in theropod dinosaurs
lil, left ilium;; lti, left tibia; pd, pedal digits; and ub, unidentified bony element. The white box indicates the position from which the sample was taken for histological analysis. Scale bars, 10 mm (a, c, d), 20 mm (b).
text-fig. 4. Skull reconstructions of representatives of riassic OTUs in left lateral view, a, Euparkeria capensis, Early Triassic (Scythian-Anisian), Beaufort Group, South Africa; redrawn from Ewer (1965). B, basal ornithischian Lesothosaurus diagnostics, Early Jurassic (Hettangian-Sinemurian), Elliot Formation, Lesotho; redrawn from Sereno (1991b). c, prosauropod sauropodomorph Plateosaurus sp., Late riassic (Norian), Knollenmergel, Germany; based on MB R. 1937. D, Eoraptor lunensis, Late Triassic (Camian), Ischigualasto Formation, Argentina; based on PVSJ 512. E, Herrerasaurus ischigualastensis, Late Triassic (Camian), Ischigualasto Formation, Argentina; redrawn from Sereno and Novas (1993). F, Coelophysis bauri, Late riassic (Norian), Chinle Formation, south-western USA; modified from Paul (1993). G, Lilienstemus lilienstemi, Late riassic (Norian), Knollenmergel, Germany; based on MB R. 2175, unpreserved elements shaded. H, Shuvosaurus inexpectatus, Late riassic (Norian), Dockum Group, Texas, USA; based on TU P 9280. Abbreviations: a, angular; aof, antorbital fenestra; d, dentary; emf, external mandibular fenestra; en, external nares; eo, exoccipital; f, frontal; itf, infratemporal fenestra; j, jugal; 1, lacrimal; m, maxilla; n, nasal; o, orbit; oc, occipital condyle; op, opisthotic; pa, parietal; pd, predentary; pm, premaxilla; pm-mf, premaxillary-maxillary fenestra; po, postorbital; pof, postfrontal; q, quadrate; qf, quadrate foramen; qj, quadratojugal; sa, surangular; saf, surangular foramen; snf, subnarial foramen; sob, supraorbital; soc, supraoccipital; sp, splenial; sq, squamosal; stf, supratemporal fenestra. Scale bars represent 10 mm (a-b) and 50 mm (c-H). in The interrelationships and evolution of basal theropod dinosaurs
text-fig. 4. Skull reconstructions of representatives of riassic OTUs in left lateral view, a, Euparkeria capensis, Early Triassic (Scythian-Anisian), Beaufort Group, South Africa; redrawn from Ewer (1965). B, basal ornithischian Lesothosaurus diagnostics, Early Jurassic (Hettangian-Sinemurian), Elliot Formation, Lesotho; redrawn from Sereno (1991b). c, prosauropod sauropodomorph Plateosaurus sp., Late riassic (Norian), Knollenmergel, Germany; based on MB R. 1937. D, Eoraptor lunensis, Late Triassic (Camian), Ischigualasto Formation, Argentina; based on PVSJ 512. E, Herrerasaurus ischigualastensis, Late Triassic (Camian), Ischigualasto Formation, Argentina; redrawn from Sereno and Novas (1993). F, Coelophysis bauri, Late riassic (Norian), Chinle Formation, south-western USA; modified from Paul (1993). G, Lilienstemus lilienstemi, Late riassic (Norian), Knollenmergel, Germany; based on MB R. 2175, unpreserved elements shaded. H, Shuvosaurus inexpectatus, Late riassic (Norian), Dockum Group, Texas, USA; based on TU P 9280. Abbreviations: a, angular; aof, antorbital fenestra; d, dentary; emf, external mandibular fenestra; en, external nares; eo, exoccipital; f, frontal; itf, infratemporal fenestra; j, jugal; 1, lacrimal; m, maxilla; n, nasal; o, orbit; oc, occipital condyle; op, opisthotic; pa, parietal; pd, predentary; pm, premaxilla; pm-mf, premaxillary-maxillary fenestra; po, postorbital; pof, postfrontal; q, quadrate; qf, quadrate foramen; qj, quadratojugal; sa, surangular; saf, surangular foramen; snf, subnarial foramen; sob, supraorbital; soc, supraoccipital; sp, splenial; sq, squamosal; stf, supratemporal fenestra. Scale bars represent 10 mm (a-b) and 50 mm (c-H).
Supplementary material 1 from: Bannikova AA, Jenkins PD, Solovyeva EN, Pavlova SV, Demidova TB, Simanovsky SA, Sheftel BI, Lebedev VS, Fang Y, Dalen L, Abramov AV (2019) Who are you, Griselda? A replacement name for a new genus of the Asiatic short-tailed shrews (Mammalia, Eulipotyphla, Soricidae): molecular and morphological analyses with the discussion of tribal affinities. ZooKeys 888: 133-158. https://doi.org/10.3897/zookeys.888.37982
: Explanation note: Figure S1. The phylogenetic relationships in Blarinella as reconstructed in MrBayes based on the extended alignment of cytb. Figure S2. The phylogenetic relationships in Blarinella as reconstructed in MrBayes based on the alignment of ApoB. Table S1. GenBank accession numbers of sequences retrieved from GenBank and newly collected sequences used in the study (marked in bold). Table S2. Primers for cytb amplification and sequencing. Table S3. The best-fit substitution models employed for each of the five partitions found by IQTREE.
Raw Data for Pd Metallene Manuscript
Open the record for dataset details and reuse information.
Pd-Al2O3 Catalyst for Ammonia
<p>Galaxy RO Crate object containing the workflow and data with the reproduction of the results published in: D. Decarolis, A. H. Clark, T. Pellegrinelli, M. Nachtegaal, E. W. Lynch, C. R. A. .Catlow, E. K. Gibson, A. Goguet, P. P. Wells (2021). <em>Spatial Profiling of a Pd/Al2O3 Catalyst during Selective Ammonia Oxidation</em> DOI: <a href="http://dx.doi.org/10.1021/acscatal.0c05356">10.1021/acscatal.0c05356</a>.</p> <p>This RO is published as part of the research data submitted for the paper <strong>Facilitating Reproducibility in Catalysis Research with Managed Workflows and RO-Crates: A Galaxy Case Study</strong>, ChemCatChem, DOI: 10.1002/cctc.202401676.</p>
Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer
<p>Polygenic risk score weights derived using LDpred for hypothyroidism and thyroid medication use.</p>
Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
<p>Different biomarkers based on genomics variants have been used to predict the response of patients treated with PD-1/programmed death receptor 1 ligand (PD-L1) blockade. We aimed to use deep-learning algorithm to estimate clinical benefit in patients with non-small-cell lung cancer (NSCLC) before immunotherapy. Peripheral blood samples or tumor tissues of 915 patients from three independent centers were profiled by whole-exome sequencing or next-generation sequencing. Based on convolutional neural network (CNN) and three conventional machine learning (cML) methods, we used multi-panels to train the models for predicting the durable clinical benefit (DCB) and combined them to develop a nomogram model for predicting prognosis. In the three cohorts, the CNN achieved the highest area under the curve of predicting DCB among cML, PD-L1 expression, and tumor mutational burden (area under the curve [AUC] = 0.965, 95% confidence interval [CI]: 0.949–0.978, <em>P</em> < 0.001; AUC =0.965, 95% CI: 0.940–0.989, <em>P</em> < 0.001; AUC = 0.959, 95% CI: 0.942–0.976, <em>P</em> < 0.001, respectively). Patients with CNN-high had longer progression-free survival (PFS) and overall survival (OS) than patients with CNN-low in the three cohorts. Subgroup analysis confirmed the efficient predictive ability of CNN. Combining three cML methods (CNN, SVM, and RF) yielded a robust comprehensive nomogram for predicting PFS and OS in the three cohorts (each <em>P</em> < 0.001). The proposed deep-learning method based on mutational genes revealed the potential value of clinical benefit prediction in patients with NSCLC and provides novel insights for combined machine learning in PD-1/PD-L1 blockade.</p>
CD3_CD68_PD_midbrain_counts
<p>This file contains quantification of interactions between CD3+ and CD68+ cells in the perivascular space of PD or neurological control midbrains.</p>
Nanofocused X-ray beam drives a hydriding phase transition in Pd nanoparticles under electrochemical control
<p>For analysis, see</p> <p>https://github.com/maxiv-science/20200372-analysis</p>
Association of PD-L1 immunoexpression with the clinicopathological characteristics and its prognostic significance in OPMD and OSCC
<p>Master chart for Oral Potentially Premalignant cases and Oral Squamous Cell carcinoma cases.</p>
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a prospectively-powered multicenter, retrospective cohort study
<p><strong>Summary </strong></p> <p>Background Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers.</p> <p>Methods This prospectively-powered multicenter, retrospective cohort study was conducted in 15 melanoma centers in Australia, China, Germany, Italy, Japan, UK, and US. We included adult patients with resected stage III BRAF V600-mutant melanoma who received either adjuvant D/T or PD-1. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included overall survival (OS), recurrence pattern and toxicity.</p> <p>Findings We included 598 patients with stage III BRAF V600-mutant melanoma who received either adjuvant D/T (n=393 [66%]) or PD-1 (n=205 [34%]) post definitive surgery between Jul 2015 and Oct 2022. At a median follow-up of 33 months (IQR 21-43), the median RFS was 51∙0 months (95%CI 41∙0-not reached [NR]) in the D/T group, significantly longer than 44∙8 (95%CI 28∙5-NR) in the PD-1 group (univariate: HR 0∙658, 95%CI 0∙498-0∙869, P=0∙003; multivariate: HR 0∙687, 95% CI 0∙512-0∙922, P = 0∙012), with comparable OS with PD-1 (multivariate, HR 1∙011, 95%CI 0∙637-1∙604, P>0∙95). Similar findings were observed using a restricted-mean-survival-time model. D/T survival benefits were consistent in most subgroups, except for older, male patients and those with V600K mutation. Among those who experienced recurrence, the proportion of distant metastases was higher in the D/T cohort. D/T had a higher incidence of treatment modification due to adverse events (AEs) than PD-1, but fewer persistent AEs.</p> <p>Interpretation In patients with stage III BRAF V600-mutant melanoma post definitive surgery, D/T yielded better RFS than PD-1, with higher transient but lower persistent toxicity, and comparable OS. D/T is potentially a superior adjuvant option compared with PD-1. </p>
Supplementary data for "Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging"
<p>Supplementary data for "Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging". The docking.zip file contains ClusPro protein/protein docking results for all binding protein variants using either murine PD-1 structure (3bikB) or human PD-1 AF2 model as receptors. The pymol session contains data and scenes used to generate the Figures in the paper.</p>
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
ClinicalTrials.gov study NCT04121442. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
ClinicalTrials.gov study NCT04174781. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
ClinicalTrials.gov study NCT06357533. IPD Sharing: YES. Countries: 21. Publications: 0.
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
ClinicalTrials.gov study NCT06831175. IPD Sharing: NO. Countries: 1. Publications: 10.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.